Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

Danish leader will face a challenging landscape among competitors ...

July 29 (UPI) -- Novo Nordisk announced Tuesday that Mike Doustdar has been appointed as the company's new CEO. Doustdar ...

Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Novo Nordisk A/V (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is ...

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...

Novo Nordisk is misunderstood by the market, creating a rare asymmetric value opportunity. Read why I rate NVO stock a Buy ...

Novo Nordisk's U.S.-listed shares shed a third of their value last week after the company cut its full-year outlook and named ...